Analysis of TNF-antagonist switch over time and associated risk factors in the Swiss Inflammatory Bowel Disease Cohort. [electronic resource]
Producer: 20151012Description: 1207-18 p. digitalISSN:- 1502-7708
- Adalimumab
- Adolescent
- Adult
- Aged
- Aged, 80 and over
- Anti-Inflammatory Agents, Non-Steroidal -- adverse effects
- Antibodies, Monoclonal -- therapeutic use
- Antibodies, Monoclonal, Humanized -- therapeutic use
- Body Mass Index
- Certolizumab Pegol
- Child
- Child, Preschool
- Cohort Studies
- Colitis, Ulcerative -- diagnosis
- Crohn Disease -- diagnosis
- Delayed Diagnosis
- Drug Substitution -- statistics & numerical data
- Drug Tolerance
- Female
- Humans
- Immunoglobulin Fab Fragments -- therapeutic use
- Infant
- Infliximab
- Male
- Middle Aged
- Polyethylene Glycols -- therapeutic use
- Risk Factors
- Switzerland
- Time Factors
- Tumor Necrosis Factor-alpha -- antagonists & inhibitors
- Young Adult
No physical items for this record
Publication Type: Journal Article; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.